|
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
|
11/06/26
|
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
|
pdf
|
|
Bausch Health Announces Third Quarter 2026 Results, Raises Guidance
|
10/28/26
|
Bausch Health Announces Third Quarter 2026 Results, Raises Guidance
|
pdf
|
|
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
|
10/28/26
|
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
|
pdf
|
|
Bausch Health Announces US$50 Million Share Repurchase Program
|
10/28/26
|
Bausch Health Announces US$50 Million Share Repurchase Program
|
pdf
|
|
Bausch Health Canada Announces Expanded Public Reimbursement for PrOKEDI® (Risperidone for Extended-Release Injectable Suspension) Across Canada for the Treatment of Schizophrenia
|
10/19/26
|
Bausch Health Canada Announces Expanded Public Reimbursement for PrOKEDI® (Risperidone for Extended-Release Injectable Suspension) Across Canada for the Treatment of Schizophrenia
|
pdf
|
|
Bausch Health Canada annonce l’élargissement du remboursement public de PrOKEDIMD (suspension injectable à libération prolongée de rispéridone) au Canada pour le traitement de la schizophrénie
|
10/19/26
|
Bausch Health Canada annonce l’élargissement du remboursement public de PrOKEDIMD (suspension injectable à libération prolongée de rispéridone) au Canada pour le traitement de la schizophrénie
|
pdf
|
|
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
|
10/12/26
|
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
|
pdf
|
|
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
|
10/12/26
|
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
|
pdf
|
|
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
|
10/06/26
|
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
|
pdf
|
|
Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
|
09/08/26
|
Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
|
pdf
|
|
PrSILIQ® (brodalumab injection) Now Reimbursed Under Alberta’s Public Drug Plan, Improving Access for Eligible Patients with Moderate to Severe Plaque Psoriasis
|
09/08/26
|
PrSILIQ® (brodalumab injection) Now Reimbursed Under Alberta’s Public Drug Plan, Improving Access for Eligible Patients with Moderate to Severe Plaque Psoriasis
|
pdf
|
|
Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
|
09/01/26
|
Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
|
pdf
|
|
Bausch Health Announces Availability of Solta Medical’s Fraxel FTX® in Australia (Australia Version)
|
08/31/26
|
Bausch Health Announces Availability of Solta Medical’s Fraxel FTX® in Australia (Australia Version)
|
pdf
|
|
Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
|
08/27/26
|
Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
|
pdf
|
|
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
|
08/17/26
|
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
|
pdf
|
|
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
|
08/06/26
|
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
|
pdf
|
|
Bausch Health Announces Second Quarter 2026 Results, Raises Guidance
|
07/29/26
|
Bausch Health Announces Second Quarter 2026 Results, Raises Guidance
|
pdf
|
|
PrELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta’s Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis
|
07/28/26
|
PrELIDEL® (pimecrolimus) cream Now Reimbursed Under Alberta’s Public Drug Plan for Eligible Patients with Mild to Moderate Atopic Dermatitis
|
pdf
|
|
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026
|
07/07/26
|
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026
|
pdf
|
|
Québec is the first province to list PrOKEDIMC (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophrenia
|
07/06/26
|
Québec is the first province to list PrOKEDIMC (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophrenia
|
pdf
|
|
Le Québec est la première province à inscrire PrOKEDIMD (suspension injectable à libération prolongée de rispéridone) sur la liste des médicaments remboursés par le régime public pour le traitement de la schizophrénie
|
07/06/26
|
Le Québec est la première province à inscrire PrOKEDIMD (suspension injectable à libération prolongée de rispéridone) sur la liste des médicaments remboursés par le régime public pour le traitement de la schizophrénie
|
pdf
|
|
Michael Goettler Resigns from Bausch Health's Board of Directors
|
07/01/26
|
Michael Goettler Resigns from Bausch Health's Board of Directors
|
pdf
|
|
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of PrOKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia
|
06/09/26
|
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of PrOKEDI® (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia
|
pdf
|
|
Bausch Health, Canada Inc. et l’Alliance pancanadienne pharmaceutique concluent avec succès leurs négociations, menant à la signature d’une lettre d’intention pour OKEDIMC (suspension injectable à libération prolongée de rispéridone) dans le traitement de la schizophrénie
|
06/09/26
|
Bausch Health, Canada Inc. et l’Alliance pancanadienne pharmaceutique concluent avec succès leurs négociations, menant à la signature d’une lettre d’intention pour OKEDIMC (suspension injectable à libération prolongée de rispéridone) dans le traitement de la schizophrénie
|
pdf
|
|
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
|
05/28/26
|
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
|
pdf
|
|
Bausch Health Announces 2026 Annual Meeting of Shareholder Results
|
05/19/26
|
Bausch Health Announces 2026 Annual Meeting of Shareholder Results
|
pdf
|
|
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
|
05/13/26
|
Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference
|
pdf
|
|
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
|
05/12/26
|
Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
|
pdf
|
|
Bausch Health Announces First Quarter 2026 Results
|
04/29/26
|
Bausch Health Announces First Quarter 2026 Results
|
pdf
|
|
Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
|
04/14/26
|
Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
|
pdf
|
|
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
|
03/31/26
|
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
|
pdf
|
|
Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
|
03/26/26
|
Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
|
pdf
|
|
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + BrilliantMD Touch Laser in Canada (French)
|
02/23/26
|
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + BrilliantMD Touch Laser in Canada (French)
|
pdf
|
|
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
|
02/23/26
|
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
|
pdf
|
|
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
|
02/19/26
|
Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres
|
pdf
|
|
Bausch Health Announces Fourth Quarter and Full-Year 2025 Results
|
02/18/26
|
Bausch Health Announces Fourth Quarter and Full-Year 2025 Results
|
pdf
|
|
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
|
02/17/26
|
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
|
pdf
|
|
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program
|
02/11/26
|
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program
|
pdf
|
|
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
|
01/23/26
|
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
|
pdf
|
|
Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
|
01/21/26
|
Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
|
pdf
|
|
Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
|
01/05/26
|
Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
|
pdf
|